Royalty Report: Drugs, Vaccine, Immune – Collection: 287545

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Vaccine
  • Immune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 287545

License Grant
The Company acquired assets that primarily comprised of a license from another party.
License Property
The assets in this Asset Purchase agreement included but not limited to the License with another party.  This license has related patents, intellectual property and related product inventory to the products below.

LUM-201 is a potential oral therapy for pediatric growth hormone deficiency (“PGHD”) and other rare endocrine disorders.

To develop and potentially commercialize our Ebola vaccine V920 product candidate and other aspects of our vaccine technology. The Ebola vaccine V920 product candidate was originally developed by the Public Health Agency of Canada and is designed to utilize the rVSV vector to induce immunity against the Ebola virus when replacing the VSV glycoprotein with corresponding glycoproteins from filoviruses.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 349382

License Grant
LIcensee obtained from Licensor a worldwide, non-exclusive, sublicensable (subject to Licensor’s consent in the United States, specified major European countries and Japan, such consent not to be unreasonably withheld) license under the specified patents and know-how that are the subject of Licensee’s exclusive license to develop, manufacture and commercialize LUM-201 for diagnostic purposes, excluding Autism Spectrum Disorders.
License Property
LUM-201, which is a growth hormone (“GH”) secretagogue, also called ibutamoren, for rare endocrine disorders where injectable recombinant human growth hormone (“rhGH”) is currently approved. LUM-201 is a tablet formulation that will be administered once daily.  LUM-201, a potential oral therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders.

LUM-201 stimulates GH via the GH secretagogue receptor, also known as the ghrelin receptor, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. LUM-201’s stimulatory effect is regulated by both circulating levels of GH and its down-stream mediator insulin-like growth factor which at supraphysiological levels feedback or negatively regulate additional release of GH from the pituitary, hence protecting against hyperstimulation of GH release. LUM-201 has been observed to stimulate endogenous GH secretion in patients who have a functional but reduced hypothalamic pituitary GH axis.

The therapeutic goal in PGHD is to restore growth, enabling short children to achieve normal height and prevent complications that could involve metabolic abnormalities, cognitive deficiencies and reduced quality of life.

Field of Use
Field of use is for the treatment of PGHD and other rare endocrine disorders.  Its diagnostic purposes is for any and all indications, excluding Autism Spectrum Disorders.

PGHD is a rare endocrine disorder occurring in approximately one in 3,500 persons aged birth to 17 years. Causes of PGHD can be congenital (children are born with the condition), acquired (brain tumor, head injuries or other causes), iatrogenic (induced by medical treatment) or idiopathic (of unknown cause). Children with untreated PGHD will have significant growth failure (potential adult heights significantly less than five feet and may have abnormal body composition with decreased bone mineralization, decreased lean body mass and increased fat mass).

IPSCIO Record ID: 345562

License Grant
English Licensor granted a nonexclusive license to Licensee to produce and characterize potential product candidates using the Company’s viral vector technology and to provide research services to Licensee during the research term which commenced on June 2019 through the end of 66 months and for up to six vaccine products based on antigens discovered via Licensee’s proprietary platform.
License Property
Viral vector technology is known as ChAdOx1 and ChAdOx2.  This platform comprises several components that, when combined, allow the developed product candidates designed to induce high and durable levels of antigen-specific T cells and B cells, to prevent and treat infectious diseases and cancer.

ChAdOx1 and ChAdOx2 are modified simian adenoviral vectors which deliver target antigens into cells to generate a specific immune response. These viruses were originally isolated from chimpanzees to avoid pre-existing immunity issues affecting the use of human adenovirus vectors.

Field of Use
Field of use is for the immunotherapy and vaccine fields.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.